Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Hematologic
Phase I
Adults
Not Available
Not Available
Dholaria, Bhagirathbhai
National
Vanderbilt University
06-30-2021
Other
VICCCTT20114
NCT03741127

Eligibility

18 Years
BOTH
NO
Inclusion Criteria:

Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol.

Subject has provided informed consent.



Exclusion Criteria:

None

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: